DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia

January 29, 2018 updated by: Hsien-Yuan Lane, China Medical University Hospital
Pharmacotherapy for schizophrenia has limitations such as residual positive and negative symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia is still a difficult clinical issue at present. According to the N-methyl-D-aspartate (NMDA) hypothesis, adjuvant NMDA-enhancing agents may have therapeutic benefit. DAAOI-2, a D-amino acid oxidase (DAAO) inhibitor, is a NMDA-enhancing agent. The aim of this project is to examine the effectiveness and safety of DAAOI-2 add-on treatment for treatment-resistant schizophrenia patients in a randomized, double-blind, placebo-controlled trial.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Pharmacotherapy for schizophrenia has limitations such as residual positive and negative symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia is still a difficult clinical issue at present. According to the N-methyl-D-aspartate (NMDA) hypothesis, many clinical trials on NMDA-enhancing agents were studied. Adjuvant NMDA-enhancing agents, including glycine, D-amino acids such as D-serine, and sarcosine (a glycine transporter I inhibitor), revealed beneficial but limited efficacy for positive and negative symptoms.

The aim of this project is to examine the effectiveness and safety of DAAOI-2 add-on treatment for treatment resistant schizophrenia patients in a randomized, double-blind, placebo - controlled trial.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Taichung, Taiwan
        • Department of Psychiatry, China Medical University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Fulfill the DSM-IV criteria of schizophrenia
  • Treatment resistant: No satisfactory response to at least two kinds of antipsychotics
  • Remain symptomatic but without clinically significant fluctuation and the antipsychotic doses are unchanged for at least 3 months
  • Have a minimum baseline total score of 70 on the Positive and Negative Syndrome Scale (PANSS)
  • Agree to participate in the study and provide informed consent

Exclusion Criteria:

  • Meet DSM-IV criteria of substance (including alcohol) abuse or dependence
  • Meet DSM-IV criteria of mental retardation
  • Serious medical or neurological illness
  • Pregnancy or lactation
  • Inability to follow protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: placebo
Drug: placebo
oral, for 6 weeks
Experimental: DAAOI-2
DAAOI-2: 500-2000mg/d
Drug: DAAOI-2
500-2000mg/d, oral, for 6 weeks

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Positive and Negative Syndrome Scale(PANSS)
Time Frame: baseline
baseline
Positive and Negative Syndrome Scale(PANSS)
Time Frame: 2 weeks after the trial
2 weeks after the trial
Positive and Negative Syndrome Scale(PANSS)
Time Frame: 4 weeks after the trial
4 weeks after the trial
Positive and Negative Syndrome Scale(PANSS)
Time Frame: 6 weeks after the trial (The end of the trial)
6 weeks after the trial (The end of the trial)
Assessment of Negative symptoms(SANS)
Time Frame: baseline
baseline
Assessment of Negative symptoms(SANS)
Time Frame: 2 weeks after the trial
2 weeks after the trial
Assessment of Negative symptoms(SANS)
Time Frame: 4 weeks after the trial
4 weeks after the trial
Assessment of Negative symptoms(SANS)
Time Frame: 6 weeks after the trial (The end of the trial)
6 weeks after the trial (The end of the trial)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
PANSS subscales
Time Frame: baseline
baseline
PANSS subscales
Time Frame: 2 weeks after the trial
2 weeks after the trial
PANSS subscales
Time Frame: 4 weeks after the trial
4 weeks after the trial
PANSS subscales
Time Frame: 6 weeks after the trial (The end of the trial)
6 weeks after the trial (The end of the trial)
Clinical Global Impression (CGI)
Time Frame: baseline
baseline
Clinical Global Impression (CGI)
Time Frame: 2 weeks after the trial
2 weeks after the trial
Clinical Global Impression (CGI)
Time Frame: 4 weeks after the trial
4 weeks after the trial
Clinical Global Impression (CGI)
Time Frame: 6 weeks after the trial (The end of the trial)
6 weeks after the trial (The end of the trial)
Global assessment of function (GAF)
Time Frame: baseline
baseline
Global assessment of function (GAF)
Time Frame: 2 weeks after the trial
2 weeks after the trial
Global assessment of function (GAF)
Time Frame: 4 weeks after the trial
4 weeks after the trial
Global assessment of function (GAF)
Time Frame: 6 weeks after the trial (The end of the trial)
6 weeks after the trial (The end of the trial)
Hamilton Depression Rating Scale (HAMD)
Time Frame: baseline
baseline
Hamilton Depression Rating Scale (HAMD)
Time Frame: 2 weeks after the trial
2 weeks after the trial
Hamilton Depression Rating Scale (HAMD)
Time Frame: 4 weeks after the trial
4 weeks after the trial
Hamilton Depression Rating Scale (HAMD)
Time Frame: 6 weeks after the trial (The end of the trial)
6 weeks after the trial (The end of the trial)
Quality of life scale (QOL)
Time Frame: baseline
baseline
Quality of life scale (QOL)
Time Frame: 2 weeks after the trial
2 weeks after the trial
Quality of life scale (QOL)
Time Frame: 4 weeks after the trial
4 weeks after the trial
Quality of life scale (QOL)
Time Frame: 6 weeks after the trial (The end of the trial)
6 weeks after the trial (The end of the trial)
"Measurement and Treatment Research to Improve Cognition in Schizophrenia [MATRICS]
Time Frame: baseline

An intergrated score from 7 domains:

  1. speed of processing: category fluency, trail making A, and digit symbol - coding from Wechsler adult intelligence scale (WAIS-III);
  2. sustained attention: continuous performance test;
  3. verbal and nonverbal working memory: backward digit span and spatial span from Wechsler memory scale (WMS-III);
  4. verbal learning and memory: word listing from WMS-III;
  5. visual learning and memory: visual reproduction from WMS-III;
  6. reasoning and problem solving: maze from Wechsler intelligence scale for children (WISC-III);
  7. social cognition: the managing emotions branch of Mayer-Salovey-Caruso emotional intelligence test (MSCEIT)
baseline
"Measurement and Treatment Research to Improve Cognition in Schizophrenia [MATRICS]
Time Frame: 6 weeks after the trial (The end of the trial)

An intergrated score from 7 domains:

  1. speed of processing: category fluency, trail making A, and digit symbol - coding from Wechsler adult intelligence scale (WAIS-III);
  2. sustained attention: continuous performance test;
  3. verbal and nonverbal working memory: backward digit span and spatial span from Wechsler memory scale (WMS-III);
  4. verbal learning and memory: word listing from WMS-III;
  5. visual learning and memory: visual reproduction from WMS-III;
  6. reasoning and problem solving: maze from Wechsler intelligence scale for children (WISC-III);
  7. social cognition: the managing emotions branch of Mayer-Salovey-Caruso emotional intelligence test (MSCEIT)
6 weeks after the trial (The end of the trial)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
China Medical University Hospital

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Ministry of Science and Technology, Taiwan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2014

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2016

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 10, 2015

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 23, 2015

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 26, 2015

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 30, 2018

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 29, 2018

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NSC-101-2314-B-039-030-MY3

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings